Loading...
•
Sep 30, 2021
ACADIA Q3 2021 Earnings Report
Reported a net sales increase of 9% compared to Q3 2020, driven by volume growth across all channels.
Key Takeaways
Acadia Pharmaceuticals reported Q3 2021 net sales of $131.6 million, a 9% increase over Q3 2020. The company is scheduled to meet with the FDA to discuss next steps towards a resubmission of the pimavanserin sNDA.
Net sales of NUPLAZID were $131.6 million, a 9% increase compared to Q3 2020.
Scheduled meeting with the FDA to discuss additional analyses supporting a potential resubmission of the pimavanserin sNDA.
Top-line results from the Phase 3 LAVENDER study evaluating trofinetide for the treatment of Rett syndrome are expected in the fourth quarter of 2021.
Top-line results from the Phase 2 study of ACP-044 for the treatment of postoperative pain following bunionectomy surgery are expected in the first quarter of 2022.
Revenue by Segment
Forward Guidance
Acadia narrowed its NUPLAZID net sales guidance to $480 to $500 million, decreased GAAP R&D guidance to $230 to $245 million, and narrowed GAAP SG&A guidance to $385 to $405 million.
Positive Outlook
- NUPLAZID net sales guidance is narrowed to $480 to $500 million from the previous range of $480 to $515 million.
- GAAP R&D is decreased to $230 to $245 million from the previous range of $250 to $270 million.
- Current R&D guidance includes approximately $25 million of stock-based compensation expense.
- GAAP SG&A guidance is narrowed to $385 to $405 million from the previous range of $385 to $415 million.
- Current SG&A guidance includes approximately $45 million of stock-based compensation expense.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...